Results 91 to 100 of about 50,819 (268)
Muscle &Nerve, EarlyView.ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza +6 more
wiley +1 more source
Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative Study
Muscle &Nerve, EarlyView.ABSTRACT Introduction/Aims The burden of myasthenia gravis (MG) is often underestimated, and studies usually focus on the symptom burden. However, treatment‐related adverse events also contribute to patients' burdens and affect their treatment decisions.
Meg Mendoza +6 more
wiley +1 more source
Discover OncologyObjective This study aims to screen and identify metabolic biomarkers and targets for methylprednisolone treatment of thymoma with myasthenia gravis (MG) through metabolomics and network pharmacology analysis, thereby improving guidance for clinical ...
Shanshan Gu +9 more
doaj +1 more source
Determinants of quality of life in Brazilian patients with myasthenia gravis
ClinicsOBJECTIVES: The aims of the current study were 1) to evaluate the reliability and validity of the Brazilian version of the 15-item Myasthenia Gravis Quality of Life Scale and 2) to investigate the quality of life of Brazilian patients with myasthenia ...
Aline Mansueto Mourão +7 more
doaj +1 more source
BMC Neurology, 2019 Background Myasthenia gravis associated takotsubo syndrome is a rare condition. This study aimed to explore its typical presentation, investigations and treatment through a systematic review of previously reported cases.
Devarajan Rathish, Minuri Karalliyadda
doaj +1 more source
Consistent improvement with eculizumab across muscle groups in myasthenia gravis
Annals of Clinical and Translational Neurology, 2020 Objective To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale ...
Renato Mantegazza +4 more
doaj +1 more source
Cytokine Profiles in Myasthenia Gravis Subgroups and the Lack of Any Effect of Immunosuppression
Muscle &Nerve, EarlyView.ABSTRACT Introduction/Aims Myasthenia gravis (MG) is a clinically and immunologically heterogeneous autoimmune disease and there is little known about the differential effects of cytokines in disease subgroups. This study aimed to compare serum cytokine profiles across distinct MG subgroups, including early‐onset MG (EOMG), late‐onset MG (LOMG), muscle‐
Merve Cebi +6 more
wiley +1 more source
BMC MedicineBackground To identify the associations between thymic pathology and the prognosis of myasthenia gravis (MG) patients. Methods In this multicenter retrospective study, 1,254 myasthenia gravis (MG) patients who underwent thymectomy across four clinical ...
Moli Fan +11 more
doaj +1 more source
Pharmacotherapy of Myasthenia Gravis
, 2015 The pharmacotherapy of Myasthenia Gravis is gradually advancing with special regard to immunospuression.
Omar, Majeed
core
IgG Subclass (IgG1‐4) and IgA Autoantibody Profiles Against Muscle‐Specific Kinase in a Greek Cohort
Muscle &Nerve, EarlyView.ABSTRACT Introduction/Aims Muscle‐specific kinase myasthenia gravis (MuSK‐MG) is an autoimmune neuromuscular disorder predominantly mediated by IgG4 autoantibodies disrupting MuSK signaling. The contribution of other isotypes remains incompletely defined. We characterized the serological profile of a Greek cohort of MuSK‐MG patients.
Sofia‐Natsοuko Gkotzamani +22 more
wiley +1 more source